Atovaquone
| Clinical data | |
|---|---|
| Trade names | Mepron | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a693003 | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 2.2–3.2 days | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.158.738 | 
| Chemical and physical data | |
| Formula | C22H19ClO3 | 
| Molar mass | 366.84 g·mol−1 | 
| 3D model (JSmol) | |
| Melting point | 216 to 219 °C (421 to 426 °F) | 
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Atovaquone, sold under the brand name Mepron, is an antimicrobial medication for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP).
Atovaquone is a chemical compound that belongs to the class of naphthoquinones. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of both ubiquinone and lawsone.